CO2018011948A2 - Procedimiento para la preparación de derivados de 1-fenilo-1,2,4- triazol sustituidos por 5-hidroxialquilo - Google Patents
Procedimiento para la preparación de derivados de 1-fenilo-1,2,4- triazol sustituidos por 5-hidroxialquiloInfo
- Publication number
- CO2018011948A2 CO2018011948A2 CONC2018/0011948A CO2018011948A CO2018011948A2 CO 2018011948 A2 CO2018011948 A2 CO 2018011948A2 CO 2018011948 A CO2018011948 A CO 2018011948A CO 2018011948 A2 CO2018011948 A2 CO 2018011948A2
- Authority
- CO
- Colombia
- Prior art keywords
- preparation
- hydroxyalkyl
- phenyl
- triazole derivatives
- derivatives substituted
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- CGRLXLHYYDSTKR-UHFFFAOYSA-N 1-phenyl-1H-1,2,4-triazole Chemical group N1=CN=CN1C1=CC=CC=C1 CGRLXLHYYDSTKR-UHFFFAOYSA-N 0.000 title 1
- -1 monofluoromethyl Chemical group 0.000 abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16168169 | 2016-05-03 | ||
| EP16168172 | 2016-05-03 | ||
| EP16168165 | 2016-05-03 | ||
| EP16168166 | 2016-05-03 | ||
| EP16168163 | 2016-05-03 | ||
| EP17160086 | 2017-03-09 | ||
| PCT/EP2017/060367 WO2017191104A1 (de) | 2016-05-03 | 2017-05-02 | Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018011948A2 true CO2018011948A2 (es) | 2018-11-22 |
Family
ID=58633014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0011948A CO2018011948A2 (es) | 2016-05-03 | 2018-11-02 | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4- triazol sustituidos por 5-hidroxialquilo |
Country Status (18)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017191115A1 (en) * | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
| TWI755393B (zh) * | 2016-05-03 | 2022-02-21 | 德商拜耳製藥股份有限公司 | 製備5-羥基烷基取代之1-苯基-1,2,4-三唑衍生物之方法 |
| US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| WO2021259852A1 (en) | 2020-06-25 | 2021-12-30 | Bayer Aktiengesellschaft | Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2653332A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP2341776A4 (en) * | 2008-09-19 | 2012-05-30 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| WO2011104322A1 (de) * | 2010-02-27 | 2011-09-01 | Bayer Pharma Aktiengesellschaft | Bis-arylverknüpfte aryltriazolone und ihre verwendung |
| ES2641205T3 (es) * | 2012-05-08 | 2017-11-08 | Bayer Pharma Aktiengesellschaft | Procedimiento para la preparación de compuestos de triazol |
| CN107074783B (zh) * | 2014-11-03 | 2020-06-05 | 拜耳制药股份公司 | 羟烷基取代的苯基三唑衍生物及其用途 |
| WO2017191115A1 (en) * | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
| TWI755393B (zh) * | 2016-05-03 | 2022-02-21 | 德商拜耳製藥股份有限公司 | 製備5-羥基烷基取代之1-苯基-1,2,4-三唑衍生物之方法 |
| US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
-
2017
- 2017-05-02 TW TW106114435A patent/TWI755393B/zh not_active IP Right Cessation
- 2017-05-02 WO PCT/EP2017/060367 patent/WO2017191104A1/de not_active Ceased
- 2017-05-02 US US16/098,238 patent/US10703742B2/en not_active Expired - Fee Related
- 2017-05-02 BR BR112018072528-5A patent/BR112018072528A2/pt active Search and Examination
- 2017-05-02 MX MX2020010365A patent/MX391356B/es unknown
- 2017-05-02 EP EP17719636.7A patent/EP3452467A1/de not_active Withdrawn
- 2017-05-02 PE PE2018002254A patent/PE20190202A1/es unknown
- 2017-05-02 MX MX2018013336A patent/MX379555B/es unknown
- 2017-05-02 CA CA3022789A patent/CA3022789A1/en active Pending
- 2017-05-02 RU RU2018142264A patent/RU2742885C2/ru active
- 2017-05-02 UY UY0001037222A patent/UY37222A/es not_active Application Discontinuation
- 2017-05-02 JP JP2018557408A patent/JP6921863B2/ja not_active Expired - Fee Related
- 2017-05-02 KR KR1020187031568A patent/KR20190003536A/ko not_active Ceased
- 2017-05-02 CN CN201780027607.0A patent/CN109071500B/zh not_active Expired - Fee Related
- 2017-05-02 AU AU2017259872A patent/AU2017259872B2/en not_active Ceased
- 2017-05-02 SG SG11201809672YA patent/SG11201809672YA/en unknown
- 2017-05-02 CN CN202110424553.XA patent/CN113105403A/zh active Pending
-
2018
- 2018-10-23 IL IL262534A patent/IL262534B/en active IP Right Grant
- 2018-10-31 CL CL2018003107A patent/CL2018003107A1/es unknown
- 2018-11-02 CO CONC2018/0011948A patent/CO2018011948A2/es unknown
-
2020
- 2020-05-21 US US16/880,933 patent/US20200299271A1/en not_active Abandoned
-
2021
- 2021-06-14 JP JP2021098486A patent/JP2021143193A/ja not_active Withdrawn
- 2021-09-22 AU AU2021236502A patent/AU2021236502A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN113105403A (zh) | 2021-07-13 |
| TW201815782A (zh) | 2018-05-01 |
| MX2018013336A (es) | 2019-05-09 |
| KR20190003536A (ko) | 2019-01-09 |
| WO2017191104A1 (de) | 2017-11-09 |
| US10703742B2 (en) | 2020-07-07 |
| RU2018142264A (ru) | 2020-06-03 |
| JP2021143193A (ja) | 2021-09-24 |
| MX391356B (es) | 2025-03-19 |
| CN109071500A (zh) | 2018-12-21 |
| EP3452467A1 (de) | 2019-03-13 |
| AU2017259872B2 (en) | 2021-06-24 |
| SG11201809672YA (en) | 2018-11-29 |
| CA3022789A1 (en) | 2017-11-09 |
| UY37222A (es) | 2017-11-30 |
| CL2018003107A1 (es) | 2019-02-22 |
| JP6921863B2 (ja) | 2021-08-18 |
| BR112018072528A2 (pt) | 2019-03-26 |
| IL262534B (en) | 2021-04-29 |
| MX379555B (es) | 2025-03-11 |
| CN109071500B (zh) | 2021-05-18 |
| RU2742885C2 (ru) | 2021-02-11 |
| JP2019514948A (ja) | 2019-06-06 |
| AU2021236502A1 (en) | 2021-10-21 |
| US20190144431A1 (en) | 2019-05-16 |
| TWI755393B (zh) | 2022-02-21 |
| AU2017259872A1 (en) | 2018-11-22 |
| RU2018142264A3 (cg-RX-API-DMAC7.html) | 2020-08-19 |
| MX2020010365A (es) | 2022-04-06 |
| IL262534A (en) | 2018-12-31 |
| US20200299271A1 (en) | 2020-09-24 |
| PE20190202A1 (es) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018011948A2 (es) | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4- triazol sustituidos por 5-hidroxialquilo | |
| PE20170945A1 (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| CL2014000384A1 (es) | Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-2-alquinil/alquenil-etil)-1h-(1,2,4) triazol sustituidos; proceso para preparar dichos compuestos; composiciones agroquímicas. | |
| CL2014000125A1 (es) | Compuesto fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-etoxi-etil)-1h-(1,2,4)triazol sustituidos; procesos para preparar dichos compuestos; uso de dichos compuestos para combatir hongos fitopatógenos. | |
| CL2014000201A1 (es) | Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-aluiniloxi-etil)-1h-(1,2,4)triazol sustituidos; procesos para preparar dichos compuestos; uso de dichos compuestos para combatir hongos fitopatógenos. | |
| CL2013003672A1 (es) | Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-2-ciclil-etil)-1h-(1,2,4)triazol sustituidos; procesos para preparar dichos compuestos; composicion agroquimica que la comprende; uso para combatir hongos fitopatógenos. | |
| AR104695A1 (es) | Compuestos fungicidas | |
| PE20190345A1 (es) | Combinaciones de compuestos activos | |
| MA34552B1 (fr) | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor | |
| EP3489232A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| CO6900159A2 (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-3-metil-butil}-1h-[1,2,4]triazol sustituidos | |
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| PH12012501391A1 (en) | Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof | |
| CL2008001074A1 (es) | Uso de compuestos de triazol, antagonistas de smo para tratar cancer. | |
| CL2014003003A1 (es) | Proceso para la preparacion de 1-[6-(morfolin—4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-ol (i – forma enol) o de 2-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1,2-dihidro-3h-pirazol-3-ona (i – forma ceto); y compuesto intermediario (2e/z)-3-(dimetilamino)-2-(1h-1,2,3-triazol-1-il) acrilato de metilo. | |
| JP2016520635A5 (cg-RX-API-DMAC7.html) | ||
| HRP20150544T1 (hr) | Derivat triazola za uporabu u lijeäśenju neuropatskih bolova i fibromialgije | |
| TN2018000126A1 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| EP3233824A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
| NI202000030A (es) | Profármacos de derivados de triazol sustituido y sus usos | |
| MX379586B (es) | 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-il)metil)-5-(2,4-difluorofenil)tetrahidrofuran-3-il)metoxi)-3-metilfenil)piperazin-1-il)-n-(2-hidroxiciclohexil) benzamida antifungica, o una sal farmaceuticamente aceptable de la misma. | |
| MY198496A (en) | Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives | |
| JP2016520636A5 (cg-RX-API-DMAC7.html) | ||
| EP3233079A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
| AR076372A1 (es) | Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5 |